Featured Research

from universities, journals, and other organizations

Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed

Date:
August 15, 2013
Source:
National Cancer Institute (NCI) at NIH
Summary:
Initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease. Long term results show the small excess of higher grade tumors in the men in the finasteride arm of the study did not translate into an increased risk of death.

In the NCI-sponsored Prostate Cancer Prevention Trial (PCPT), initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease.

New findings reported in NEJM on August 15, 2013, based on follow-up of trial participants for up to 18 years, showed that survival of the men on finasteride was equivalent to men who did not take the drug and the reduction in risk of prostate cancer persists.

Among nearly 19,000 eligible men who underwent randomization, prostate cancer was diagnosed in 10.5 percent of those in the finasteride group and 14.9 percent of those in the placebo group, a 30 percent reduction in risk. For the men diagnosed with prostate cancer, 10-year survival from time of diagnosis was equivalent between study groups overall (78 percent), in those with low-grade cancers (82 percent), and in those with high-grade cancers (73 percent) providing reassurance that the small excess of higher grade tumors in the men in the finasteride arm of the study did not translate into an increased risk of death.

Previous studies based on the original 2003 analysis had already suggested that the increase in high-grade disease may have been due to prostate gland shrinkage and increased sensitivity in detecting higher grade cancers. In fact, the PCPT was not designed specifically to address the question of high-grade disease.

Since 2011, drugs such as finasteride have had to carry a warning that they may increase the risk of high-grade prostate cancer; they have never been approved for the prevention of the disease. Specifically, there was concern that the increase in high-grade cancers detected among men receiving finasteride would result in more deaths. This new analysis was undertaken, in part, to understand if such concern was warranted.


Story Source:

The above story is based on materials provided by National Cancer Institute (NCI) at NIH. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, Howard L. Parnes, Lori M. Minasian, Paul A. Godley, M. Scott Lucia, Leslie G. Ford. Long-Term Survival of Participants in the Prostate Cancer Prevention Trial. New England Journal of Medicine, 2013; 369 (7): 603 DOI: 10.1056/NEJMoa1215932

Cite This Page:

National Cancer Institute (NCI) at NIH. "Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed." ScienceDaily. ScienceDaily, 15 August 2013. <www.sciencedaily.com/releases/2013/08/130815161443.htm>.
National Cancer Institute (NCI) at NIH. (2013, August 15). Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2013/08/130815161443.htm
National Cancer Institute (NCI) at NIH. "Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed." ScienceDaily. www.sciencedaily.com/releases/2013/08/130815161443.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins